BIO-KOREA
26.5.2021 15:02:11 CEST | Business Wire | Press release
As one of the most important global bio-health conventions, BIO KOREA 2021 International Convention has garnered great attention from home and abroad. To facilitate the discussion on the future bio-health industry in the ‘COVID-19 era’, the BIO KOREA 2021 to be held on June 9 to 21 will evolve around the theme of “New Normal: Breaking Barriers with Bio Innovation”.
BIO KOREA organizing committee announced the main programs, deep-diving into business strategies in the post-pandemic era.
The Four Programs Focusing on Biohealth Industry and Business
BIO KOREA 2021 Business Forum will focus on a virtual partnering system allowing attendees to schedule virtual meetings to maximize their business development and licensing potential.
International participation continues to grow. Numerous companies from 20+ countries already joined and are expected to showcase their advanced technologies at BIO KOREA 2021.
As an event involving various kinds of discussion, BIO KOREA attracts not only leading biohealth companies in Korea such as SK Chemicals, Chong Kun Dang, ShinPoong Pharm, Kolon Life Science, etc, but also promising SMEs like PharmCADD, WELT, Oncocross, Biot Korea, all of which are eager to grow their business. 24-hour meeting slots will strengthen your digital network across time zones. Also, company presentations will be livestreamed on the official BIO KOREA platform.
The Exhibition will be held both online and on-site, as a hybrid format, which will showcase the cutting-edge technologies and products of exhibitors in various ways. 300+ exhibitors, from start-up to global enterprise, will be at BIO KOREA’s exhibition. Participants can meet on-site exhibitors through live streaming on the online platform during the event.
There will be a Digital Healthcare-themed pavilion introducing the industrial rookies of Digital Wellness, Mobile Healthcare, Digital Therapeutics, Big Data, and AI, etc. Also, COVID-19 show room will show participants how biohealth serves as a cure for the pandemic.
The Conference of BIO KOREA will consist of valuable expert-level lectures regarding the most pressing industry topics including Digital Health, Drug Development, and Post COVID-19. BIO KOREA 2021 conference covering 18 topics with 170+ speakers, will bring the most up-to-date conversations of biohealth both online and on-site.
Invest Fair is an event where pharmaceuticals, bio, and healthcare companies that are advancing into the global market and developing new drugs introduce their leading technology, vision and strategy to the investors. Along with online hosting, it maintains the participants’ attendance with impressive lineups of 19 companies such as Lunit, Tium BIO, VaxcellBio and Genesystem.
BIO KOREA 2021 will be available both Online and On-site
BIO KOREA presents invaluable information on the industry’s trends around the world. This year, the global audience will have a front-row seat to discover and see the latest technology. All BIO KOREA programs will be livestreamed from June 9 to June 21. The program at a glance is on https://www.biokorea.org/program/schedule.asp .
For more updates: https://www.biokorea.org
About BIO KOREA
BIO KOREA serves as a venue place for practical business correspondence as well as international information and technology exchange, invigorating the bio industry. For 15 years, BIO KOREA has been a place of bringing together various international academics, professionals, and CEOs of global bio companies to obtain, exchange, and discuss diverse affairs. It has been providing abundant opportunities to enhance competitive edges within the convergence industry centered around biotechnology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005412/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 09:00:00 CEST | Press release
NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom